Healthcare Stocks Rise as Investors Rotate Away From Tech
AbbVie, Eli Lilly, and J&J near all-time highs as investors seek shelter in pharma amid tech uncertainty.
If you've been watching your tech-heavy portfolio sweat lately, you're not alone — and it looks like a growing number of investors are quietly tiptoeing out of tech and into the relative calm of healthcare. Shares of AbbVie, Eli Lilly, and Johnson & Johnson were all on track to hit all-time highs on Friday, a pretty loud signal that Wall Street's appetite for biopharmaceuticals is making a serious comeback.
Healthcare has long played the role of the boring-but-reliable cousin at the investment family reunion. When riskier, growth-oriented sectors like tech start wobbling — whether from interest rate pressure, valuation concerns, or just plain nervousness — money tends to flow toward industries that sell things people genuinely can't stop buying, like prescription drugs and medical treatments. That defensive quality is exactly what's drawing investors in right now.
Read more Strategy's June 30 Ex-Dividend Date: What Investors Should Know →
The simultaneous surge of three heavyweight pharma names toward record territory isn't a coincidence — it reflects a broader sector rotation that traders watch closely. When blue-chip names across an entire industry move together like this, it usually means institutional money (think big funds and asset managers, not just individual investors) is deliberately repositioning. In plain English: the smart money appears to be hedging its bets.
For everyday investors, this kind of rotation is worth paying attention to. It doesn't necessarily mean tech is doomed — sector rotations happen all the time and can reverse quickly. But it does suggest that diversifying into healthcare could be worth a look if your portfolio is heavily tilted toward one corner of the market. Names like AbbVie, Lilly, and J&J hitting record highs while markets are choppy elsewhere is the kind of thing that tends to get people's attention.
Continue reading at MarketWatch.com
